Abstract: Falciparum malaria is a major global health problem and is third leading cause of death after HIV and tuberculosis. Although, several targets and related drugs are available, yet the parasite evolves a resistance mechanism to most of the existing drugs. Under such circumstances, it is imperative to explore antimalarial drug targets and effective drugs. Malaria is an interesting case of evolutionary selection and several host genetic factors have been selected in response to Plasmodium falciparum infection, such as hemoglobin variants, glucose-6-phosphate dehydrogenase (G6PD) and pyruvate kinase deficiency. Among these G6PD deficiency is one of the most studied host genetic factor that confer resistance to malaria in endemic and non endemic region. We have studied G6PD deficiency in Falciparum malaria patients and ethnically matched controls in non endemic region of 170 blood samples. G6PD deficiency in samples was detected by Fluorescent spot test. The samples were incubated with reaction mixture, spotted and visualized (366 nm) under ultraviolet light. Results indicate that the frequency of % G6PD deficiency is 9.2 in males and 7.14 in females in non endemic region. On the basis of our data and earlier studies, we conclude that G6PD deficiency is more prevalent in those areas where the frequency of malaria infection is high. G6PD is a selective force against the pressure of malaria in endemic regions while in non endemic regions the burden of malaria is seasonal and low which accounts for the deficiency of enzyme in conferring protection against malaria.